Vorapaxar in Patients with diabetes mellitus and previous myocardial infarction findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial

Circulation

Volumn 131, Issue 12, 2015, Pages 1047-1053

  Cavender, Matthew A ^a   Scirica, Benjamin M ^a   Bonaca, Marc P ^a   Angiolillo, Dominick J ^b   Dalby, Anthony J ^c   Dellborg, Mikael ^d   Morais, Joao ^e   Murphy, Sabina A ^a   Ophuis, Ton Oude ^f   Tendera, Michal ^g   Braunwald, Eugene ^a   Morrow, David A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c MILPARK HOSPITAL   (South Africa)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e Cardiology Division   (Portugal)

^f CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^g MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Coronary disease; Diabetes mellitus; Myocardial infarction; Secondary prevention

Indexed keywords

INSULIN; VORAPAXAR; LACTONE; PYRIDINE DERIVATIVE; THROMBIN RECEPTOR;

ADULT; AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; THROMBOSIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DEATH; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME; TRENDS;

AGED; DEATH; DIABETES MELLITUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PYRIDINES; RECEPTORS, THROMBIN; SECONDARY PREVENTION; STROKE; THROMBOSIS; TREATMENT OUTCOME;

EID: 84928336118     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.013774     Document Type: Article

References (20)

1. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, Wilson PW, Alberts MJ, D'Agostino R, Liau CS, Mas JL, Röther J, Smith SC Jr, Salette G, Contant CF, Massaro JM, Steg PG; REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350-1357. doi:10.1001/jama.2010.1322.
2. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndromes. JAMA. 2007;298:765-775. doi:10.1001/jama.298.7.765.
3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234. doi:10.1056/NEJM199807233390404.
4. Fox CS, Coady S, Sorlie PD, D'Agostino RB Sr, Pencina MJ, Vasan RS, Meigs JB, Levy D, Savage PJ. Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham Heart Study. Circulation. 2007;115:1544-1550. doi:10.1161/CIRCULATIONAHA.106.658948.
5. Sabatine MS, Braunwald E. Will diabetes save the platelet blockers? Circulation. 2001;104:2759-2761.
6. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011;123:798-813. doi:10.1161/CIRCULATIONAHA.109.913376.
7. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000;35:922-928.
8. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Théroux P, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001;104:2767-2771.
9. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM; TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118:1626-1636. doi:10.1161/CIRCULATIONAHA.108.791061.
10. Morrow DA, Antman EM, Murphy SA, Qin J, Ruda M, Guneri S, Jacob AJ, Budaj A, Braunwald E; TIMI Study Group. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial. Am Heart J. 2007;154:1078-84, 1084.e1. doi:10.1016/j.ahj.2007.07.027.
11. Scirica BM, Bonaca MP, Braunwald E, De Ferrari, GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf, F, Wilcox R, Morrow DA; TRA 2°P-TIMI 50 Steering Committee Investigators. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: A prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet. 2012;380:1317-1324. doi:10.1016/S0140-6736(12)61269-0.
12. Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E; TRA 2°P-TIMI 50 Investigators. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial. Am Heart J. 2009;158:335-341.e3. doi:10.1016/j.ahj.2009.06.027.
13. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404-1413. doi:10.1056/NEJMoa1200933.
14. Cavender MA, Rao SV, Ohman EM. Major bleeding: management and risk reduction in acute coronary syndromes. Expert Opin Pharmacother. 2008;9:1869-1883. doi:10.1517/14656566.9.11.1869.
15. Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: The Treating to New Targets (TNT) study. Circulation. 2012;125:1979-1987. doi:10.1161/CIRCULATIONAHA.111.088591.
16. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504. doi:10.1056/NEJMoa040583.
17. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long- Term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet. 2001;358:527-533.
18. James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J, Nicolau JC, Spinar J, Storey RF, Stevens SR, Wallentin L; PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: A substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010;31:3006-3016. doi:10.1093/eurheartj/ehq325.
19. Angiolillo DJ, Jakubowski JA, Ferreiro JL, Tello-Montoliu A, Rollini F, Franchi F, Ueno M, Darlington A, Desai B, Moser BA, Sugidachi A, Guzman LA, Bass TA. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol. 2014;64:1005-1014. doi:10.1016/j.jacc.2014.06.1170.
20. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26:2181-2188.